LAUSR

e13048Background: In a previous meta-analysis which published in 23rd NCCN Annual Conference, we reported that the addition of cyclin-dependent kinases 4 and 6 inhibitors (CDKi) to endocrine therapy (ET) improved progression-free survival (PFS) for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). This update aims to further confirm and compare the efficacy of different CDKi for HR+/HER2− ABC. Methods: We identify relevant randomized clinical trials (RCTs) published prior to February 2018. Direct and indirect evidence for PFS was calculated hazard ratios (HRs) and 95% credible intervals (CIs) using random-effects network meta-analysis. Quality of evidence was appraised with GRADE criteria. The PROSPERO registry number is 42018081105. Results: Seven RCTs including a total of 3,854 patients were identified. Combining direct effects showed that the addition of CDKi to ET significantly improved PFS for HR+/HER2− ABC (HR 0.54; 9...